Geode Capital Management LLC Reduces Position in Progyny, Inc. (NASDAQ:PGNY)

Geode Capital Management LLC reduced its stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,826,429 shares of the company's stock after selling 96,527 shares during the period. Geode Capital Management LLC owned 2.14% of Progyny worth $31,512,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in shares of Progyny by 341.4% in the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after purchasing an additional 1,246 shares during the period. Signaturefd LLC boosted its holdings in Progyny by 1,355.0% in the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after buying an additional 1,355 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after buying an additional 1,526 shares during the period. KBC Group NV increased its stake in Progyny by 84.6% in the 4th quarter. KBC Group NV now owns 4,669 shares of the company's stock worth $81,000 after buying an additional 2,140 shares in the last quarter. Finally, Entropy Technologies LP raised its holdings in Progyny by 5.5% during the fourth quarter. Entropy Technologies LP now owns 47,883 shares of the company's stock valued at $826,000 after acquiring an additional 2,499 shares during the period. 94.93% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PGNY shares. Bank of America increased their target price on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Canaccord Genuity Group lifted their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research report on Friday, February 28th. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a research report on Monday, March 31st. Finally, JPMorgan Chase & Co. lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Eight equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Progyny presently has a consensus rating of "Hold" and an average target price of $23.64.

Progyny Stock Up 2.3 %

PGNY traded up $0.50 on Tuesday, hitting $21.87. The company had a trading volume of 1,426,368 shares, compared to its average volume of 1,743,543. The company has a market cap of $1.87 billion, a PE ratio of 37.71, a PEG ratio of 2.39 and a beta of 1.33. The business's fifty day simple moving average is $21.93 and its 200 day simple moving average is $18.94. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $33.84.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.